TECVAYLI (teclistamab) Patient Card

Please carry this card with you regularly.

SHOW THIS CARD to any healthcare professional involved in your care, and upon arrival at the hospital

TECVAYLI®
(teclistamab)

TECVAYLI can cause side effects that could be severe and life-threatening, such as cytokine release syndrome (CRS), a severe immune response that can be triggered by various factors and a variety of medicines. In addition, TECVAYLI can affect the nervous system, leading to immune effector cell-associated neurotoxicity syndrome (ICANS).

PATIENT'S NAME:

_____

Important Safety Information for Patients

Seek immediate medical help if you experience any of the following:

- Fever (38°C or higher)
- Chills
- Fast heartbeat
- Difficulty breathing
- Nausea
- Headache
- Feeling dizzy

These may be signs and symptoms of a serious immune reaction (CRS)

- Confusion
- Sensation of altered alertness
- Difficulty speaking and writing (including changes in handwriting)
- Muscle weakness, slow movements, difficulty walking
- Seizures
- Memory impairment

These are some of the possible effects on the nervous system; some of them may be signs and symptoms of (ICANS)

If you have **any** of the symptoms listed on this card, call your doctor or seek emergency medical attention right away! These are not all the possible side effects of TECVAYLI. Tell your doctor if you have any side effect that bothers you or does not go away.

IMPORTANT TO REMEMBER: Stay close to a treatment center for two days after receiving the first three doses of TECVAYLI (usually two doses of step-up dosing and one maintenance dose). Your doctor may instruct you to stay near the treatment center for additional periods of time.

Treating Physician

TREATING PHYSICIAN'S NAME:

_____

TREATING PHYSICIAN'S PHONE NUMBER:

_____

HOSPITAL NAME AND ADDRESS:

_____

PHONE NUMBER:

_____

Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TECVAYLI injections (step-up dosing schedule of the product):

DATE OF FIRST STEP-UP DOSE:

DATE OF SECOND STEP-UP DOSE:

DATE OF FIRST MAINTENANCE DOSE*:

*This is the first full dose of treatment (1.5 mg/kg)

Important Safety Information for Healthcare Professionals

Cytokine release syndrome (CRS) or neurotoxicity (ICANS) of life-threatening severity may occur in patients receiving TECVAYLI. For more information, see the physician's leaflet.

The majority of CRS and neurotoxicity observed following TECVAYLI administration were Grade 1 and 2. CRS may involve several body systems. Monitor the patient for signs and symptoms of CRS and neurotoxicity. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

Reporting Side Effects

This format and its contents have been updated and approved by the Ministry of Health in October 2023.
For more information, see the patient package insert.
You can report side effects to the Ministry of Health using the online form for reporting side effects on the Ministry of Health homepage: www.health.gov.il, or by clicking on the link:
https://sideeffects.health.gov.il/

In addition, you can report side effects directly to Janssen Israel, by calling: 09-9591111.